By definition, human embryonic stem cells [hESCs] and human induced pluripotent stem cells [hiPSCs] are pluripotent cells that have the ability to indefinitely self-renew and become any cell type in the body. Because of these attributes, PSCs have become an important scientific tool and are spurring advancements in basic research, disease modelling, drug development, and regenerative medicine. No longer do researchers have to rely on ethically plagued embryonic stem cells. With the revelation of induced pluripotency in 2007, there is a new avenue for therapeutic use of stem cells via allogenic and autologus methods.
Ten years ago, stem cell researchers were studying how bone marrow transplants could be used to cure blood diseases, such as leukemia and sickle cell anaemia. Now with the advances in stem cell research and induced pluripotency, more patient-specific therapies are being explored. Autologous hiPSC-derived retinal pigment epithelium cell sheets can be used to treat patients with age-related macular degeneration. Allogenic treatment of MSCs have shown great promise in helping patients afflicted with irritable bowel syndrome. Autologous use of adult stem cells differentiated down the chondrogenic lineage can be used to aid in patients with osteoarthritis. While clinical use of stem cells has shared its part in many ethical debates, promising work is being done to meet patients' needs for generalised and specialised treatments.
To aid in multiple facets of stem cell research, Lonza offers an expansive portfolio of products that will help simplify your reprogramming, proliferation and differentiation of stem cells. From Lonza's new L7TM hiPSC Reprogramming and hPSC Culture system, to highly published adult stem cells and NucleofectorTM Kits for genome editing and reprogramming; Lonza offers a variety of products to support your research and improve your workflow.